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http://dx.doi.org/10.1016/j.ccr.2013.09.021SUMMARYpRb and p53 are two major tumor suppressors. Here, we found that p53 activates expression of Pirh2 and
KPC1, two of the three ubiquitin ligases for p27. Loss of p53 in the absence of Skp2, the third ubiquitin ligase
for p27, shrinks the cellular pool of p27 ubiquitin ligases to accumulate p27 protein. In the absence of pRb and
p53, p27 was unable to inhibit DNA synthesis in spite of its abundance, but could inhibit division of cells that
maintain DNA replication with rereplication. This mechanism blocked pRb/p53 doubly deficient pituitary and
prostate tumorigenesis lastingly coexistent with bromodeoxyuridine-labeling neoplastic lesions, revealing
an unconventional cancer cell vulnerability when pRb and p53 are inactivated.INTRODUCTION
The prototype tumor suppressor retinoblastoma protein (pRb) is
a transducer between the cell’s environment and gene expres-
sion machinery (Burkhart and Sage, 2008). Fully active pRb
recruits chromatin-modifying proteins to the promoters of E2F
target genes to repress genes for DNA replication, which can
be sufficiently potent and permanent to induce cellular senes-
cence (Chicas et al., 2010). Upstream, pRb is regulated by
phosphorylation by cyclin-dependent kinases (CDKs). Various
signaling pathways can activate expression of relevant CDKs
and cyclin-dependent kinase inhibitors (CKIs) to inactivate
pRb (such as by cyclin D1/Cdk4 to induce tumorigenesis) or to
activate pRb (such as by p16Ink4A to induce senescence)
(Sherr, 2012).Significance
Because pRb and p53 together are responsible for most antitu
and explains in large part why cancers are difficult to treat. W
guard to be activated by the loss of p53 and pRb to block the o
esis lasted well into mouse old age. A counterintuitive feature
neoplastic cells before they were eliminated by apoptosis. T
treated by Skp2 inhibitors, but inhibition of DNA synthesis
practiced.
CanThe other major tumor suppressor, p53, is activated by onco-
genic stress, such as the loss of pRb, directly or indirectly via Arf
(Sherr, 2012). Activated p53 switches on its target genes to
induce cell-cycle arrest, senescence, and apoptosis to safe-
guard against tumorigenesis.
In experimental settings, most of the cell’s intrinsic antitumor
mechanisms seem to function via p53, pRb, or both. Indeed,
combined deletion of Rb1 (encoding pRb) and Trp53 (encoding
p53) is very effective in inducing tumors in a wide spectrum of tis-
sues in mice. Clinically, inactivation of both pRb and p53 is
frequent in various cancers and may explain, in large part, why
cancers are difficult to treat. In recent studies, investigators
have discovered that deleting Skp2, a subunit of the Skp1,
Cullin1, F-box protein complex, Cullin-Ring ubiquitin ligase 1
(SCF CRL1) E3 ubiquitin ligase, can induce apoptosis to blockmor mechanisms, their combined loss is frequent in cancers
e discovered that deleting Skp2 in mice allowed a p27 safe-
therwise aggressive tumorigenesis. This block of tumorigen-
of this block is that DNA synthesis persisted in the blocked
hus, pRb/p53 doubly deficient tumors might be effectively
might not be a useful diagnostic criterion as traditionally
cer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Inc. 645
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Figure 1. Skp2 Deletion Blocks pRb/p53
Doubly Deficient, but Not pRb/p27 Doubly
Deficient, Pituitary Tumorigenesis
(A–C) Hematoxylin and eosin (H&E)–stained sec-
tions of pituitary samples at 7 weeks of age.
Higher-magnification views of the intermediate
lobe (IL) are presented under lower-magnification
ones. PL, posterior lobe.
(D) Pituitary sections of indicated genotypes were
stained as indicated. For the Skp2+/+;POMC-
Cre;Rb1lox/lox;Trp53lox/lox genotype, we selected
pituitaries that were not deformed bymacroscopic
tumors. PCNA, proliferating cell nuclear antigen;
pHH3, phosphohistone 3; TUNEL, terminal deox-
ynucleotidyl transferase deoxyuridine triphos-
phate nick-end labeling.
(E) Quantification of cells shown in (D) that stained
positive with Ki67, pHH3, or TUNEL.
(F) A representative image of Skp2–/– pituitaries
stained for p27.
Scale bars are as marked. Quantitative data are
presented as averages ± SEM. Statistical analyses
were carried out by Student’s t test. See also
Figure S1.
Cancer Cell
Blocking pRb/p53 Doubly Deficient TumorigenesispRb-deficient pituitary tumorigenesis (Wang et al., 2010) or
induce p53-independent senescence to block tumorigenesis in
Arf–/– mice or Pten-deficient prostate (Lin et al., 2010). These
two findings might have conformed to the existing paradigm
that p53 is activated to inhibit pRb-deficient tumorigenesis,
and, vice versa, that pRb is activated to inhibit p53-deficient
tumorigenesis, when Skp2 is absent. Skp2 deletion, however,
was found not to block tumorigenesis by N-ethyl-N-nitrosourea
(Wang et al., 2010) or by Myc-driven lymphomagenesis (Old
et al., 2010).
In this study, we sought to determine whether combined loss
of pRb and p53 would leave cells defenseless against tumori-
genesis in the absence of Skp2.
RESULTS
Skp2 Deletion Blocks pRb/p53 Doubly Deficient
Pituitary Tumorigenesis
Deleting Rb1 using POMC-Cre was sufficient to induce melano-
troph tumorigenesis across the entire intermediate lobe (IL) in
thepituitary (Figure1A),whereasdeletingTrp53didnot doso (Fig-
ure S1A available online). Combined deletion of Rb1 and Trp53
greatly accelerated IL tumorigenesis (Figure 1B), demonstrating646 Cancer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Inc.the safeguarding role of p53 following
loss of Rb1. Remarkably, Skp2 deletion
still blockedthis tumorigenesis (Figure1B).
In comparison, p27 knockout (KO)
induced IL hyperplasia (Fero et al., 1996;
Kiyokawa et al., 1996; Nakayama et al.,
1996) (Figure S1B) and accelerated pRb-
deficient IL tumorigenesis to an extent
similar to deletion of Trp53, but Skp2 was
dispensable in this context (Figure 1C).
Surprisingly, although the Skp2KO ILs
did not develop tumors following co-dele-tion ofRb1 and Trp53 in them, they appeared to contain asmuch
of the proliferation markers Ki67 and proliferating cell nuclear
antigen (PCNA) as the Skp2 wild-type (WT), pRb/p53 doubly
deficient ILs, which were undergoing rapid tumorigenesis (Fig-
ure 1D). Quantification of Ki67-positive cells on a percentage
basis showed a reduction of about or less than twofold, but
this finding was statistically significant (Figure 1E). In the same
samples, the mitotic marker phosphohistone 3 (pHH3) was
reduced threefold, suggesting a more significant inhibition in
cell division (Figures 1D and 1E). Consistent with the substantial
presence of proliferation markers, senescence-associated
b-galactosidase (SA-b-gal) staining was negative in
Skp2–/–;POMC-Cre;Rb1lox/lox;Trp53lox/lox IL (data not shown).
Apoptosis was similarly infrequent in these two genotypes as
measured by terminal deoxynucleotidyl transferase deoxyuri-
dine triphosphate nick-end labeling (TUNEL) staining (Figures
1D and 1E), demonstrating that, indeed, p53 functioned to
induce apoptosis in Rb1-deficient pituitary tumorigenesis in the
absence of Skp2 (Wang et al., 2010). Thus, the complete block-
ing of the highly accelerated tumorigenesis coexisted, unexpect-
edly, with abundant proliferation markers (also see Figure S1C).
Another unexpected finding was that Skp2–/–;POMC-Cre;
Rb1lox/lox;Trp53lox/lox melanotrophs contained more p27 protein
AC
D
B E Figure 2. Skp2/Rb1/Trp53 Triply Deficient
Mouse Embryo Fibroblasts Show Higher
DNA Replication and Rereplication, Accu-
mulation at 8N, and Proliferation Speed of
Wild-Type Mouse Embryo Fibroblasts
(A) Quantification of senescence-associated
b-galactosidase (SA-b-gal) marker in mouse em-
bryo fibroblasts (MEFs) of the indicated geno-
types. DKO, double-knockout; KO, knockout.
(B) Human breast cancer cell lines with known pRb
and p53 status (as indicated) were transduced
with lentiviruses expressing green fluorescent
protein (GFP) or miRNA hairpins targeting Skp2
(miSkp2). Five days after transduction, the same
number of cells were plated. SA-b-gal staining was
performed 3 days later.
(C and D) DNA content assessed by fluorescence-
activated cell sorting (FACS) analysis of MEFs with
the indicated genotypes. WT, wild type.
(E) Cell proliferation of the indicated MEFs is
measured by counting cell numbers.
Quantitative data are presented as averages ±
SEM. Statistical analyses were carried out by
Student’s t test. ***p < 0.002. FACS analysis re-
sults are representative of three experiments. See
also Figure S2.
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Blocking pRb/p53 Doubly Deficient Tumorigenesisthan Skp2–/– melanotrophs (Figures 1D and 1F; Figure S1C). This
finding was controlled with staining of p27–/– pituitary (Fig-
ure S1D). p27 accumulated in the nuclei, and p27-abundant
nuclei were larger, suggesting accumulation of more DNA.
Taken together, these results provide indications that, in the
absence of Skp2, codeletion of Rb1 and Trp53 could further in-
crease p27 protein levels, resembling a safeguard response, but
that this high-level p27 is unable to inhibit expression of prolifer-
ation markers and induce senescence in the absence of pRb
and p53. Nevertheless, the highly accelerated tumorigenesis
was blocked.
Deleting Trp53 in Skp2KO Mouse Embryo Fibroblasts
Activates a pRb Safeguard to Induce Senescence
To further investigate the above-described unexpected findings,
we generated mouse embryo fibroblasts (MEFs) of the same
genotypes to study how Skp2 deletion blocked pRb/p53 doubly
deficient tumorigenesis. We used adeno-Cre to delete Trp53,
Rb1, or both in MEFs controlled by parallel infection with
adenovirus expressing green fluorescent protein (adeno-GFP).
To simplify the text, we hereinafter refer to the various
MEFs as p53KO, double-knockout pRbp53DKO, or Skp2KO;
pRbp53DKO, for example.
Inactivation of p53 can immortalize Skp2WT MEFs but, to the
contrary, it induces senescence in Skp2KO MEFs (Lin et al.,
2010). In Figures 2A and S2A and 2B, we show, as measured
by SA-b-gal staining, that Skp2WT;p53KO MEFs were pre-Cancer Cell 24, 645–659, Nvented from senescence but that
Skp2KO;p53KO MEFs senesced more
than Skp2KO MEFs. To study how
p53KO paradoxically induced more
senescence in Skp2KO MEFs, and to
determine whether combined deletion ofRb1 would disable the senescence, we deleted Rb1 in
Skp2KO;p53KO MEFs (resulting in Skp2KO;pRbp53DKO
MEFs) and prevented senescence (Figure 2A). To model thera-
peutic inhibition of Skp2, we performed Skp2 knockdown in
the human breast cancer cell lines Hs578T and HCC1143, which
contain functional pRb but are deficient for p53, and MDA-
MB468 and BT549, which are deficient for both pRb and p53.
Two tandem microRNA 30 (miR30)-based hairpins targeting
Skp2 effectively reduced Skp2 protein and increased p27 pro-
tein in these cell lines (Sun et al., 2006) (Figure S2C). SA-b-gal
staining revealed senescence in Hs578T cells, but not in MDA-
MB468 cells, following Skp2 knockdown (Figures 2B and S2D).
Thus, inactivation of p53 and Skp2 together activated a pRb
safeguard to induce senescence. With additional loss of pRb,
this line of antitumor defense is disabled, consistent with the
abundant presence of proliferation markers in Skp2–/–;POMC-
Cre;Rb1lox/lox;Trp53lox/lox IL.
Deleting Trp53 and Rb1 Induces DNA Rereplication
Notably, although the Skp2KO;pRbp53DKO genotype dis-
abled senescence in MEFs and induced proliferation markers
in IL, it induced no tumorigenesis. We subjected MEFs of
relevant genotypes to fluorescence-activated cell sorting
(FACS) analysis to study this unusual phenotype. As ex-
pected, deletion of Rb1 or Trp53 increased S phase cells
(DNA content between 2N and 4N) and G2 phase cells (4N)
(Figure 2C).ovember 11, 2013 ª2013 Elsevier Inc. 647
Cancer Cell
Blocking pRb/p53 Doubly Deficient TumorigenesisUnexpectedly, deletion of Rb1 or Trp53 also generated more
cells with DNA content larger than 4N (>G2). Combined deletion
of Rb1 and Trp53 increased this population to 20% (Figure 2C).
The continuous distribution of the larger DNA content indicated
DNA rereplication, which is defined as refiring of certain DNA
replication origins before the entire set of chromosomeswas fully
duplicated (Arias and Walter, 2007). These findings reveal that
pRb inhibits DNA rereplication and p53 safeguards against it.
Notably, though combined loss of pRb and p53 did not synergis-
tically increase S phase cells, it did for DNA rereplication (Fig-
ure 2C). Thus, a significant portion of elevated DNA synthesis
activity during tumorigenesis following loss of pRb and p53
might be in the form of rereplication.
Codeleting Trp53 and Rb1 in Skp2KO Mouse Embryo
Fibroblasts Induces Accumulation of DNA Rereplicating
Cells by Mitotic Entry Delay
Consistent with previous reports that increased p27 in Skp2KO
MEFs inhibited mitotic cyclin-Cdk (Nakayama et al., 2004),
Skp2KO MEFs showed an increased G2 population and an 8N
peak. There was no accumulation of cells between 4N and 8N
(Figure 2D), however. This profile indicates no DNA rereplication
(as defined above), but the fully duplicated chromosomes failed
to segregate into daughter cells before they were fully duplicated
again.
Deletion of Trp53 in Skp2KO MEFs, which induced senes-
cence in them (Figure 2A), induced less DNA rereplication than
p53KO MEFs (Figures 2C and 2D). Because pRb was activated
in Skp2KO;p53KO MEFs to induce senescence (Figure 2A), a
more active pRb might have inhibited DNA rereplication as
well. Deletion of Trp53 also abolished the 8N peak, suggesting
that a more active pRb also blocked chromosome reduplication,
likely due to the inhibition of DNA synthesis.
Skp2KO;pRbp53DKO MEFs, which were prevented from
senescence, showed more S phase cells and DNA rereplication
than Skp2KO;p53KO MEFs with return of the 8N peak, resulting
in a total of 32% cells with DNA content larger than 4N (Fig-
ure 2D). This profile, together with the events leading to it,
suggests that Skp2KO;pRbp53DKO allowed DNA rereplication
to generate cells withmore than 4NDNA content, and these cells
gradually accumulated to an 8N peak. We further found that
pHH3-positive cells were reduced from 1.13% in pRbp53DKO
MEFs to 0.69% in Skp2KO;pRbp53DKO MEFs. These findings
indicate the presence of a mitotic entry delay and are consis-
tent with the significant decrease in pHH3-positive cells
in Skp2–/–;POMC-Cre;Rb1lox/lox;Trp53lox/lox ILs (Figure 1D),
whereas increased S phase and DNA rereplication explains the
abundant presence of Ki67-positive and PCNA-positive cells
(Figures 1D and 1E).
We counted cells to determine actual proliferation. We
found that Skp2KO;pRbp53DKO MEFs proliferated at the
speed of WT MEFs, despite much larger S phase popula-
tions. pRbp53DKO MEFs, despite S phase size similar to
Skp2KO;pRbp53DKO MEFs, proliferated much faster than the
latter, resulting in about threefold more cells at day 8 (Figure 2E).
This difference in cell numbers resembled the tumorigenic poten-
tials of these two genotypes in the pituitary. Similarly, human
breast cancer cell lines MDA-MB468 and BT549 (mimicking
pRbp53DKO)proliferatedmuch faster thanMDA-MB468-miSkp2648 Cancer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Incand BT549-miSkp2 (mimicking Skp2KO;pRbp53DKO), although
the latter did not senesce (Figure 2B; Figures S2D and S2E).
These MEF studies modeled findings from the pituitary
and provide insights into the unusual phenotypes of the
Skp2KO;pRbp53DKO genotype. Chromosome separation fail-
ure restricted actual cell proliferation, whereas DNA rereplication
sustained the presence of abundant proliferation markers.
p53 Loss Induces a p27 Safeguard
We next determined the molecular mechanisms for the pheno-
types of Skp2KO;pRbp53DKO MEFs. Our finding that p27
protein levels were higher in Skp2–/–;POMC-Cre;Rb1lox/lox;
Trp53lox/lox IL than in Skp2–/– IL (Figures 1D and 1F) suggested
an elevation of a p27 safeguard by combined deletion of Rb1
and Trp53. We performed western blot analysis to determine
whether p27 protein levels in Skp2KO;pRbp53DKO MEFs also
mimicked those in the pituitary. As expected, Skp2KO MEFs
contained more p27 protein than Skp2WT MEFs (Figure 3A,
lanes 1 and 3) (Nakayama et al., 2000). Combined deletion of
Rb1 and Trp53 did not change p27 protein levels in Skp2WT
MEFs (Figure 3A, lanes 1 and 2), but further increased p27 pro-
tein levels in Skp2KO MEFs (Figure 3A, lanes 3 and 4). Thus,
MEFs again mimicked IL.
We investigated whether deleting Rb1 or Trp53 alone could
further increase p27 protein in Skp2KO MEFs. We found
that Skp2KO;p53KO MEFs (Figure 3A, lane 12), but not
Skp2KO;pRbKO MEFs (Figure 3A, lane 8), contained increased
p27 protein levels. Because p53 is gradually activated with pas-
sages of cultured MEFs (Figure S3A, lanes 1 and 2), deletion of
Trp53 in late-passage Skp2KO MEFs induced higher amounts
of p27 (Figure S3A, lanes 6 and 7). Deletion of Rb1 activated
p53 in early-passage MEFs (Figure S3A, lane 3), which might
explain why combined deletion of Trp53 and Rb1 induced the
most p27 protein in Skp2KO MEFs (Figure 3A).
These findings explain why deletion of Trp53 in Skp2KOMEFs
induced higher levels of p27, which inhibits S phase cyclin-
dependent kinases. Consequently, pRb is less phosphorylated
and therefore more active. The activated pRb in turn inhibits
DNA synthesis to induce senescence. This role of pRb as a trans-
ducer between inhibition of S phase cyclin-dependent kinases
and inhibition of DNA synthesis is essential because
Skp2KO;pRbp53DKO MEFs resumed DNA synthesis and failed
to senesce. In comparison, because Skp2KO;pRbp53DKO
MEFs are delayed for mitotic entry, the inhibition of mitotic
cyclin-dependent kinases (by high p27 levels) can inhibit mitotic
entry without activated pRb.
To determine the functional significance of the high p27 in
blocking mitotic entry, we knocked down p27 in Skp2KO;
pRbp53DKOMEFs with two p27-targeting hairpins (Figure S3B).
Short hairpin 2 (sh2) reduced p27 protein in Skp2KO;
pRbp53DKO MEFs to below that in Skp2WT;pRbp53DKO
MEFs, abolished the 8N peak and reduced 4N to 8N cells (Fig-
ure S3C), and increased proliferation of Skp2KO;pRbp53DKO
MEFs faster than Skp2WT;pRbp53DKO MEFs (Figure S3D).
sh1 knocked down p27 to a lesser degree and reduced 4N to
8N cells and increased proliferation to a smaller extent. Thus,
accumulation of 4N to 8N DNA content and inhibition of pro-
liferation of pRbp53DKO MEFs by Skp2 deletion was highly
dependent on high p27 protein levels. When we used a.
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Figure 3. Deletion of Trp53 Triggers Further Stabilization of p27 Protein in Skp2KO Mouse Embryo Fibroblasts
(A) Western blot analysis of indicated proteins in mouse embryo fibroblasts (MEFs) of indicated genotypes transduced in parallel by adenovirus expressing green
fluorescent protein (adeno-GFP) or adeno-Cre (CRE). KO, knockout; WT, wild type.
(B) Cell extracts were prepared fromMEFs of indicated genotypes at the indicated time points following the addition of cycloheximide (CHX), and the amounts of
p27 protein were measured by western blot analysis in comparison to tubulin. p27 protein level quantification is presented under the gels.
(C) Cell extracts were prepared from MEFs of indicated genotypes at indicated time points after being cultured in serum-containing media following serum
starvation for 3 days. The p27 protein level was determined by western blot analysis. The cyclin A protein level is shown to indicate cell-cycle progression, and the
tubulin level is shown to indicate loading amounts. FBS, fetal bovine serum.
See also Figure S3.
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Blocking pRb/p53 Doubly Deficient Tumorigenesiscytomegalovirus (CMV) promoter to overexpress p27 in
Skp2WT;pRbp53DKO MEFs (Figure S3E), p27 protein levels
increased less than twofold (Figure S3F), cells did not accumu-
late 8N DNA content (data not shown), and proliferation rates
were only slightly reduced (Figure S3G), suggesting that p27 pro-
tein degradation is the major regulator of p27 levels and func-
tions in Skp2WT;pRbp53DKO MEFs.
The further increases in p27 protein levels were not associated
with increases in p27 mRNA levels (Figure S3H), but they were
associated with more stable p27 proteins (Figure 3B). This
finding indicated that Skp2-independent p27 degradationmech-
anisms were reduced by deletion of Trp53 in Skp2KO MEFs.
That deletion of Trp53 did not induce higher p27 in Skp2WT
MEFs suggests that Skp2 possesses sufficient p27 degradation
activity to compensate for reduction in other p27 protein degra-
dation mechanisms.
In addition to Skp2, p27 is ubiquitinated by KPC1 and Pirh2
ubiquitin ligases, which function primarily at early time points
of cell-cycle entry (Hattori et al., 2007; Kamura et al., 2004).
We used serum starvation release to determine whether Trp53
deletion affected p27 protein degradation within this time win-
dow. Figure 3C shows that Skp2KO did not prevent reduction
of p27 protein levels at early time points (hours 8, 12, and 15),Canbut prevented its further reduction at hours 22 and 25. Trp53
deletion or combined Trp53 and Rb1 deletion did not affect the
kinetics of p27 protein reduction in Skp2WT MEFs (data not
shown), but prevented p27 protein reduction at hours 8, 12,
and 15 in Skp2KO MEFs (Figure 3C). This finding suggests that
Trp53 deletion impaired the ability of KPC1 and/or Pirh2 to
degrade p27.
Interestingly, Pirh2 was previously identified as a p53 target
gene (Leng et al., 2003). We used the Transcription Regulatory
Element Database (Xuan et al., 2005) to study whether the
KPC1 gene promoter contains a p53 binding site, which is a
ten-nucleotide consensus sequence repeated once with a
spacer of 0 to 13 nucleotides (el-Deiry et al., 1992; Wei et al.,
2006) (Figure S4A). The promoter of p21, a canonical p53 target
gene, contains a p53 binding site with a matched first half and
onemismatched second half. (We call it a 0,1 site.) The Pirh2 pro-
moter contains a 0,1 site, and the KPC1 promoter contains a 1,1
site (Figure S4B). Skp2 and p27 promoters contain a 1,2 site and
a 2,1 site, respectively.
The chromatin immunoprecipitation (ChIP) experiments
shown in Figure 4A demonstrate that activation of p53 in WT
MEFs by doxorubicin (DOX) stimulated recruitment of p53 to
the promoters of p21, Pirh2, and KPC1, but not Skp2 andcer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Inc. 649
Figure 4. p27 Ubiquitin Ligases Pirh2 and KPC1 Are p53 Target Genes
(A) The results of chromatin immunoprecipitation assays with anti-p53 and control immunoglobulin G (IgG) following doxorubicin (DOX) treatment of wild-type
(WT) mouse embryo fibroblasts (MEFs). Fold enrichment (anti-p53/IgG) for the indicated promoters is presented. GAPDH, glyceraldehyde 3-phosphate dehy-
drogenase.
(B) RT-quantitative PCR (RT-qPCR) of the indicated genes in WT MEFs following DOX treatment, normalized with GAPDH.
(C) Western blot of the indicated MEFs following treatment with DOX as in (B). KO, knockout.
(D and E) Expression of Pirh2 (D) and KPC1 (E) in MEFs transduced in parallel by adeno-GFP and adeno-Cre. Values were normalized with GAPDH.
(F) Western blots of Pirh2 and KPC1 before and after deletion of Trp53.
(G and H) Same as (D) and (E) with an additional sample in which p53 was ectopically expressed, as marked inside the bars. CMV, cytomegalovirus.
(I) Western blots of Skp2KO;p53KO MEFs without or with ectopic p53 expression.
Quantitative data are presented as average ± SEM. Student’s t test was used for statistical analysis. *p < 0.05; **p < 0.01; ***p < 0.002; NS, p > 0.05. See also
Figure S4.
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the ChIP results, the expression levels of Pirh2 and KPC1 were
stimulated by DOX, although to smaller degrees than the stimu-
lation of p21 expression; but DOX did not stimulate expression of
Skp2 or p27 (Figure 4B). The western blots show that p53, p21,
Pirh2, and KPC1 proteins were increased, and that Skp2 protein650 Cancer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Incwas decreased, by DOX treatment (Figure 4C). We then
confirmed that DOX counterintuitively decreased p27 protein
levels (Figure 4C, lanes 1 and 2). Notably, DOX also reduced
p27 protein levels in Skp2KO MEFs (Figure 4C, lanes 3 and 4).
Thus, strong p53 activation and acute Trp53 deletion have oppo-
site effects on p27 protein levels. We explored the possibility that.
Cancer Cell
Blocking pRb/p53 Doubly Deficient Tumorigenesisthese changes in protein levels were due to changes in cell-cycle
profiles by DOX. We found that under the conditions we used,
DOX did not dramatically change cell-cycle profiles of WT or
Skp2KO MEFs (Figure S4C).
We next determined the effects of Trp53 deletion on the
expression of Pirh2 and KPC1. Figures 4D and 4E show that
Trp53 deletion alone or with Rb1 reduced mRNA levels of Pirh2
and KPC1 in both Skp2WT and Skp2KO MEFs. The effects of
Trp53deletionwere smaller thanTrp53 andRb1 codeletion, likely
because p53 was not highly activated in cultured MEFs before
Rb1 was deleted (Figures 3A and S3A). The western blots show
that Pirh2 and KPC1 protein levels also decreased following
deletion of Trp53 (Figure 4F). Skp2 expression was not reduced
following Trp53 deletion or codeletion with Rb1 (Figure S4D).
When we reexpressed p53 in Skp2KO;p53KOMEFs, expression
of Pirh2 andKPC1 increased (Figures 4Gand4H) andp27protein
levels decreased (Figure 4I). These results suggest that the
combined reduction in Pirh2 and KPC1 expression shrinks the
pool of the ubiquitin ligases for p27 further in Skp2KO;p53KO
MEFs and therefore further increases p27 protein accumulation.
Knockdown of Pirh2 or KPC1 can increase p27 protein in
various human and mouse cells (Hattori et al., 2007; Kamura
et al., 2004). For our study, we ectopically expressed Pirh2 and
KPC1 in Skp2KO;pRbp53DKOMEFs to determine their negative
effects on high p27 levels. Although we succeeded in increasing
Pirh2 levels by expression of CMV-huPirh2, expression of CMV-
huKPC1 increased KPC1 protein levels only slightly in these
MEFs (Figure S4E). Under these conditions, expression of
Pirh2, KPC1, or both reproducibly decreased p27 protein levels,
reduced 4N to 8N cells, and increased proliferation (Figures
S4E–S4G), but all these effects were smaller than those
observed with p27 knockdown (Figures S3B–S3D). In MDA-
MB468 andBT549 breast cancer cell lines with Skp2 knockdown
(mimicking Skp2KO;pRbp53DKO MEFs), expression of CMV-
huPirh2 and CMV-huKPC1 also increased proliferation, most
effectively in BT549 cells (Figures S4H–S4K). These results
confirmed the functions of Pirh2 and KPC1 in promoting p27
degradation and proliferation, but the extent of their overexpres-
sion and phenotypes is cell type–dependent.
Skp2 Deletion Blocks pRb/p53 Doubly Deficient
Prostate Tumorigenesis
We sought to determine whether our findings regarding the pitu-
itary and MEFs were applicable to another tissue. Although Rb1
deletion is sufficient to induce pituitary tumorigenesis, it requires
combined deletion of Trp53 to induce tumorigenesis in the brain
(Marino et al., 2000), lung (Meuwissen et al., 2003), bone (Walkley
et al., 2008; Berman et al., 2008), prostate (Zhou et al., 2006),
ovary (Flesken-Nikitin et al., 2003), breast (Jiang et al., 2010),
and liver (McClendon et al., 2011), suggesting that these tissues
may mount a stronger p53 safeguard following Rb1 deletion. We
studied the prostate. PB-Cre4;Rb1lox/lox;Trp53lox/lox mice devel-
oped rapid and invasive prostate cancer (Zhou et al., 2006). The
prostate tumors became lethal from 6months and killed all hosts
(n = 58) within 1 year (Figure 5A) (Zhou et al., 2006). In contrast, all
Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox mice (n = 32) survived, as
WT mice did, for the 19-month period (Figure 5A). Pathological
diagnoses for these two cohorts are shown in Figure 5B.
Prostatic intraepithelial neoplasias (PINs) were divided into fourCangrades (Park et al., 2002). At 3 to 4 months, PINs developed
in both cohorts (also see Figure S5A). PINs in PB-Cre4;
Rb1lox/lox;Trp53lox/lox mice were of higher grades and quickly
progressed to invasive carcinoma (Figures 5B and 5C; Fig-
ure S5B) and gross tumors during the 5- to 7-month period,
when 20 of 42 mice died. In the 8- to 9-month period, most
tumors had become macroscopic and all mice died by the
end of the ninth month. In contrast, PINs in Skp2–/–;PB-Cre4;
Rb1lox/lox;Trp53lox/lox mice never progressed beyond the PIN
stage in a total of 26 mice examined, 6 of which were examined
at 15 to 22 months.
Figures 5D and 5F show that PIN lesions in Skp2–/–;PB-
Cre4;Rb1lox/lox;Trp53lox/lox mice contained higher levels of p27,
asmeasured by immunohistochemical and western blot analysis
of dissected ventral and anterior lobes, than they did in Skp2–/–
glands. Nuclei expressing higher p27 protein levels were
larger. PCNA expression was also high in Skp2–/–;PB-Cre4;
Rb1lox/lox;Trp53lox/lox PINs (Figure 5E).
We used Ki67 staining to compare the proliferation status of
PINs. Normal glands of WT and Skp2–/– mice contained few
Ki67-positive cells, and PINs contained more of them (Figures
6A and 6B). Remarkably, the abundance of Ki67-positive cells
was similar between PINs in PB-Cre4;Rb1lox/lox;Trp53lox/lox
mice and PINs in Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox mice.
The presence of pHH3, on the other hand, was significantly
reduced from 2.23% to 1.26% (Figures 6C and 6F). If PINs in
Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox mice were undergoing
DNA rereplication with mitotic entry block, as demonstrated by
the MEF model of this genotype (Figure 2D), their nuclei should
accumulate larger amounts of DNA. We used 40,6-diamidino-2-
phenylindole (DAPI) and Feulgen stains to study this and found
that nuclei in PINs of the Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox
genotype contained significantly more DAPI and Feulgen
staining than the other three genotypes (Figures 6D, 6E, and 6G).
Thus, the ability of Skp2 deletion to block pRb/p53 doubly
deficient tumorigenesis and the mechanisms underlying this
block were essentially the same in the prostate and the pituitary,
as modeled in MEFs.
Lifelong Block in Bromodeoxyuridine Labeling Prostatic
Intraepithelial Neoplasias
We next addressed the possibility that S phase Skp2KO;
pRbp53DKO MEFs (as determined by DNA content) and proli-
ferating Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox PINs (as deter-
mined by Ki67 and PCNA expression) might not actually be
synthesizing DNA as reasons for slow proliferation of MEFs
and absence of tumorigenesis for PINs. Cells containing more
than 4N DNA content due to rereplication were found to cease
DNA synthesis by activating p53-dependent checkpoints (Zhu
et al., 2004). If cells of the Skp2KO;pRbp53DKO genotype had
ceased DNA synthesis, a mechanism to inhibit DNA synthesis
(and therefore tumorigenesis) following rereplication in the
absence of pRb and p53 would be implicated.
We first addressed this issue by analyzing bromodeoxyuridine
(BrdU)-labeled (30 minutes) Skp2KO;pRbp53DKO MEFs in par-
allel withWT and pRbp53DKOMEFs. For these three genotypes,
cells defined as being in S phase by DNA content on the x-axis
(positions indicated by yellow arrows) were shifted upward to
become BrdU-positive on the y-axis (positions indicated by redcer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Inc. 651
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Figure 5. Deletion of Skp2 Blocks pRb/p53 Doubly Deficient Prostate Tumorigenesis inside Prostatic Intraepithelial Neoplasia Stages
(A) Kaplan-Meier survival analysis of two cohorts of mice with indicated genotypes. One Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox mouse died from fighting at
9.4 months without prostate tumors.
(B) Pathological diagnoses of prostate lesions in mice of indicated genotypes in four age groups. Each prostate was serially sectioned and the most advanced
lesions were the diagnoses. PIN, prostatic intraepithelial neoplasia.
(C–E) Sections of prostates frommice of four genotypes at the indicated ages stained with hematoxylin and eosin (H&E) (C), anti-p27 (D), and anti-proliferating cell
nuclear antigen (anti-PCNA; E). Invasive carcinoma (Inv Ca) and a PIN-III lesion are marked. WT, wild type.
(F) Western blots of isolated ventral prostates (VPs) and anterior prostates (APs) from 3- to 4-month-old mice. A macroscopic tumor was included as marked.
See also Figure S5.
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Blocking pRb/p53 Doubly Deficient Tumorigenesisarrows), demonstrating that they were actively synthesizing
DNA during the labeling period (Figure 7A). The ratios of BrdU-
positive cells versus BrdU-negative cells were similar between652 Cancer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier IncpRbp53DKO MEFs and Skp2KO;pRbp53DKO MEFs (2.0 and
1.7, respectively), but much higher than the ratio of WT MEFs
(0.3), consistent with the results shown in Figures 2C and 2D..
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Figure 6. Comparisons of Proliferation Markers and Nuclear Sizes in Prostate of the Indicated Genotypes
(A–E) Sections of prostates frommicewith indicated genotypes at same ages as those shown in Figure 5Cwere stained with hematoxylin and eosin (H&E; A), anti-
Ki67 (B), anti-phosphohistone 3 (anti-pHH3) (C), 40,6-diamidino-2-phenylindole (DAPI; D), and Feulgen (E).
(F) Quantification of Ki67-positive cells and pHH3-positive cells from (B) and (C), respectively.
(G) DAPI-stained slides were quantified using an iCys Research Imaging Cytometer and iCys Cytometric Analysis Software.
Quantitative data are presented as averages ± SEM. Student’s t test was used for statistical analysis.
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Blocking pRb/p53 Doubly Deficient TumorigenesisCells containing more than 4N DNA content were also largely
BrdU-positive. The ratios of BrdU-positive cells with more than
4N DNA to BrdU-negative cells with more than 4N DNA were
5.7 for both pRbp53DKO and Skp2KO;pRbp53DKO MEFs, but
1.1 for WT MEFs. Thus, there was no indication of a pRb- andCanp53-independent inhibitory checkpoint effect on DNA synthesis
in response to DNA rereplication.
We labeled mice with BrdU (2 hr) to determine whether pros-
tate PINs were actively synthesizing DNA. We found numerous
BrdU-positive cells in PINs of both genotypes, although labelingcer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Inc. 653
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Blocking pRb/p53 Doubly Deficient Tumorigenesisfrequency was reduced from 14.85% to 9.39% by the deletion of
Skp2 (Figures 7B and 7C). Although this was a statistically signif-
icant reduction, it was less than twofold. We noticed that BrdU-
positive nuclei in Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox PINs
were larger than those in PB-Cre4;Rb1lox/lox;Trp53lox/lox PINs
(compare the two insets in Figure 7B). Figure 7D shows that
35.7% of BrdU-positive cells contained larger nuclei in
Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox PINs, compared to 7.6%
in PB-Cre4;Rb1lox/lox;Trp53lox/lox PINs. These findings suggest
that DNA synthesis activities in Skp2–/–;PB-Cre4;Rb1lox/lox;
Trp53lox/lox PINs derived largely from DNA rereplication, explain-
ing the presence of larger nuclei in them. Furthermore, BrdU-
positive and larger nuclei also contained higher p27, as shown
by double-staining for BrdU and p27 (Figure 7E).
The results discussed in this section solidify the salient feature
of theSkp2 deletion-mediated block of pRb/p53 doubly deficient
tumorigenesis. In the absence of pRb and p53, deregulation of
DNA replication in the form of rereplication persists in neoplastic
lesions that are apparently blocked for life by higher levels of
p27. Figure S6 shows more examples of BrdU-labeling PINs
in four Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox mice ages 11 to
22 months.
Blocked Skp2KO;pRbp53DKO Prostatic Intraepithelial
Neoplasia Cells Succumb to Apoptosis
Although pRb/p53 doubly deficient prostate tumorigenesis did
not progress beyond PINs in Skp2–/– mice as old as 22 months,
the PIN lesions persisted coexistent with active DNA synthesis.
Although entry to mitosis was blocked, as indicated by signifi-
cant reduction in pHH3-positive cells (Figures 6C and 6F;
Figure S6), more than half of the pHH3-positive cells were in
metaphase. Mitotic figures were also present in hematoxylin
and eosin–stained sections of blocked PIN lesions. These fea-
tures appeared inadequate to explain the lifelong block of pRb/
p53 doubly deficient prostate tumorigenesis in Skp2–/– mice
and would be compatible for selection of resistant cells.
To determine whether this block of tumorigenesis also
involved cell elimination, we measured the rates of apoptosis
in these PINs. TUNEL stain–positive cells were about 5.3%
in pRbp53DKO PINs and increased to 8.4% in Skp2KO;
pRbp53DKO PINs, which is not statistically significant (Figures
8A and 8D). Invasive carcinomas showed similar rates of
apoptosis as measured by TUNEL staining. Detection of acti-
vated caspase 3 (aCasp3) yielded similar results. We next used
nuclear condensation and fragmentation morphology (also
called apoptotic bodies or pyknosis) to detect apoptosis (Fig-Figure 7. Sustained Active DNA Synthesis in Skp2KO;pRbp53DKO Mo
Prostatic Intraepithelial Neoplasias
(A) Representative fluorescence-activated cell sorting analysis plots (from three
yuridine (BrdU) content by anti-BrdU staining. The numbers of BrdU-positive and
black circles, and the ratios are indicated in black numbers above the circles. Num
red numbers. DKO, double-knockout; KO, knockout.
(B and C) Prostate sections from BrdU-injected mice with indicated genotypes w
(C). WT, wild type.
(D) Quantification of normal-sized and larger BrdU-positive nuclei as portions of
(E) Prostate sections from BrdU-injected mice with indicated genotypes were st
Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox sample, which was taken from a 21.7-mo
containing enlarged nuclei with high p27 and BrdU incorporation.
Quantitative data in (C) and (D) are presented as averages ± SEM. Student’s t te
Canure 8B, inset a). We unexpectedly found that morphologically
apoptotic cells were TUNEL-positive (Figure 8B, inset b) as
well as TUNEL-negative (Figure 8B, inset c). Similarly, cells
with condensed nuclei (by DAPI staining) were positive or nega-
tive for aCasp3 (Figure 8B, insets d and e). After we confirmed
the ability of our TUNEL and aCasp3 staining to detect apoptosis
by examining intestinal villi (Figure S7), we reevaluated apoptosis
by combining TUNEL staining with morphological assessment.
The results (Figures 8C and 8D) show that apoptosis rates
remained similar with determination by TUNEL alone for DKO
PINs, but increased twofold in invasive cancer and triple-
knockout (TKO) PINs. Areas with as much as 20% apoptotic
cells were frequently observed in TKO PINs. Figure 8C (black
arrows in a, b, and c) indicates a typical stepwise process of
late apoptosis leading to the elimination of the cell. The block
of pRb/p53 doubly deficient prostate tumorigenesis in Skp2–/–
mice therefore was not solely due to cytostatic mechanisms.
Apoptotic elimination of blocked Skp2KO;pRbp53DKO PIN
cells could contribute to the lifelong block of tumorigenesis by
reducing the possibility for the emergence of resistant cells by,
for example, epigenetically silencing p27 expression.
DISCUSSION
Tumorigenesis is a multistep process. Because of the cells’
intrinsic antitumor safeguards, the first oncogenic events seldom
succeed. pRb and p53 tumor suppressors are major effectors of
antitumor safeguards and are therefore frequently inactivated in
cancer. To learn how to treat cancers after all the antitumor
mechanisms exemplified by pRb and p53 have been exhausted,
we conducted the current study. To completely and irreversibly
inactivate pRb and p53, we deleted the genes encoding them.
In this context, we discovered that deletion of Skp2 unmasked
a Trp53 deletion-induced safeguard to elevate p27 protein
levels. In the absence of Skp2, loss of activated p53 shrinks
the pool of p27 ubiquitin ligases further by reducing expression
of the p27 E3 ligases Pirh2 and KPC1 and therefore accumulates
p27 protein further. This rise of p27 in Skp2KO;p53KO cells
effectively inhibited the S phase to the extreme of cellular senes-
cence. Critically, additional deletion of Rb1 disabled this senes-
cence antitumor mechanism. Not only DNA replication but also
rereplication became uninhibitable, even in the presence of
high levels of p27. These findings add a dramatic piece of evi-
dence for the importance of keeping at least one of these two
major tumor suppressors for the prevention and treatment of
cancer.use Embryo Fibroblasts and in Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox
experiments) of DNA content by propidium iodide staining and bromodeox-
BrdU-negative cells in the regular cell cycle were determined within the dotted
bers of cells with > 4NDNA contentswere similarly analyzedwith red boxes and
ere stained with BrdU (B), and quantification of BrdU-positive cells is shown in
the entire BrdU-positive cell populations is shown.
ained with 40,6-diamidino-2-phenylindole (DAPI), anti-BrdU and anti-p27. The
nth-old mouse, shows persistence of prostatic intraepithelial neoplasia cells
st was used for statistical analysis. See also Figure S6.
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Figure 8. Blocked Skp2–/–;PB-Cre4;Rb1lox/lox;Trp53lox/lox Prostatic Intraepithelial Neoplastic Cells Succumb to Apoptosis
(A) Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling (TUNEL) staining of prostate sections of the indicated genotypes. WT,
wild type.
(B) Comparison of apoptosis detection by nuclear morphology (inset a), TUNEL stain (insets b and c), and activated caspase 3 (aCasp3) and 40,6-diamidino-2-
phenylindole (DAPI) costains (insets d and e) in a microscopic tumor. H&E, hematoxylin and eosin.
(C) Representative H&E-stained prostatic intraepithelial neoplasia (PIN) section of the indicated genotypes. Lower panels show higher-magnification views of
areas indicated by black arrowheads in the corresponding upper panels. Black arrows indicate typical apoptotic morphologies as described in the text.
(D) Quantification of apoptosis rates in the indicated lesions by three different methods as marked.
Quantitative data are presented as averages ± SEM. Student’s t test was used for statistical analysis. **p < 0.01; ***p < 0.002; NS, p > 0.05.
See also Figure S7.
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that pRb/p53 doubly deficient prostate tumorigenesis in the
absence of Skp2 was blocked lastingly. This unique coexistence
of BrdU-labeling neoplastic lesions and a tumor-free life gener-
ated a counterintuitive preclinical model of complete block of
tumorigenesis. In addition to revealing a vulnerability of pRb/
p53 doubly deficient tumors, this model suggests an unconven-
tional concept for the diagnosis, treatment, and management of
the worst types of cancer. At the surface level, detection of abun-
dant proliferation markers would immediately lead to the diag-
nosis of a more aggressive cancer carrying a poor prognosis,
whereas in fact they could be lastinglyblockedneoplastic lesions.
Up to now, tumor block has been associated with dramatic
reduction of proliferation markers down to the extremes of
cellular senescence. Although ostensibly elevated to block
tumorigenesis, cellular senescence, themost studied safeguard,
could also secrete cytokines and growth factors to promote
tumorigenesis (Coppe´ et al., 2010; Krtolica et al., 2001; Kuilman
and Peeper, 2009). Recent evidence shows that oncogenic Nras
induced senescence in hepatocytes to induce liver cancer when
the senescence cells were not cleared (Kang et al., 2011) and
that DOX treated Wnt1-induced mammary tumors more effec-
tively in the absence of p53 induced cellular senescence than
in its presence (Jackson et al., 2012).
Persistent DNA rereplication could provide different ways to
overcome tumor block and promote tumorigenesis. DNA rerepli-
cation is logically a source for gene amplification and genomic
instability. On an ongoing basis, these changes can generate
new mutations that inhibit p27 expression or promote p27
protein degradation and/or nuclear export to disable the block
to pRb/p53 doubly deficient tumorigenesis. This scenario is
expected to lead to rapid tumorigenesis because pRb and p53
are already inactivated. The fact that this scenario did not mate-
rialize up to the old age of 22months of mouse life is surprising. It
is possible, however, that this blocking mechanism for pRb/p53
doubly deficient tumorigenesis will delay tumor progression to
the end stage only within the longer time frames of typical human
cancers. On the other hand, our findings may suggest that Skp2
inactivation also stabilizes the genome via mechanisms yet to be
identified. Further studies are required to determine the effects of
inhibiting Skp2 on established tumors that are caused by inacti-
vation of pRb and p53 but likely have undergone additional
mutations during tumorigenesis.
Targeting Skp2 to treat cancer has already been actively pur-
sued. The finding that Skp2 deletion can induce p53-indepen-
dent senescence (Lin et al., 2010) broadens its application to
p53-deficient cancers, and a recent report has described a
Skp2 inhibitor with this ability preclinically (Chan et al., 2013).
Our present study broadens its application further to include
pRb/p53 doubly deficient cancers and sheds more light on the
design of Skp2 inhibitors. Protein degradation in the ubiquitin
proteasome system (Ciechanover, 2005) proceeds via a set of
hierarchic steps starting with target-specific polyubiquitination
and ending in degradation of polyubiquitinated proteins in the
proteasomes. For Skp2-mediated p27 ubiquitination and degra-
dation, the most target-specific step is the interaction between
SCF(CRL1)Skp2/Cks1 with T187 phosphorylated p27, and an in-
hibitor blocking this interface has recently been identified (Wu
et al., 2012). Inhibitors targeting the interaction between Skp2Canand Skp1 in SCF E3 (Chan et al., 2013; Chen et al., 2008) blocks
ubiquitination of p27 together with other substrates of SCFSkp2,
but they might spare substrates of SCF E3s employing other
F-box proteins. Further upstream are inhibitors targeting the
cullin subunit in all CRL E3 ligases (Soucy et al., 2009). Inhibitors
of ubiquitin-conjugating enzymes (E2s) have also been identi-
fied. Targeting CDC34, which functions with CRLs, inhibited
not only p27 ubiquitination but also a larger group of CRL
substrates (Ceccarelli et al., 2011). Although the above-named
inhibitors and their designs can all inhibit Skp2-mediated p27
ubiquitination with varying degrees of selectivity, they do not
inhibit Pirh2 and KPC1, because they are not CRL-type E3s
and do not depend on CDC34 as E2 for the ubiquitination of p27.
Proteasome inhibitors, by definition, do not target specific
proteins or specific groups of proteins. Impressively, however,
the proteasome inhibitor bortezomib was approved by the U.S.
Food and Drug Administration and has demonstrated remark-
able efficacy in treating multiple myeloma and mantle cell lym-
phoma. Stabilization of p27 might be an important mechanism
for its therapeutic efficacy, although other effects caused by
nonspecific accumulation of proteins might also be responsible,
especially for its side effects. In this respect, the proteasome
inhibitor argyrin A (Nickeleit et al., 2008) exhibited antitumor
activities in a p27-dependent manner. Because argyrin A is a
more specific proteasome inhibitor than bortezomib (Nickeleit
et al., 2008), its intriguing effects could suggest that truly specific
inhibition of proteasomes could indeed effectively treat cancer
‘‘specifically’’ through p27 stabilization. It will be important to
determine whether this occurs because inhibiting proteasomes
disabled the whole cellular pool of p27 E3s, including Skp2,
Pirh2, KPC1, and likely others (Cao et al., 2011). Our study
provides a basis for explaining why pan-inhibition of p27 degra-
dation mechanisms would be more effective than specific
inhibition of Skp2 for cancer treatment.EXPERIMENTAL PROCEDURES
Mice
POMC-Cre mice (Balthasar et al., 2004), PB-Cre4 mice (Wu et al., 2001),
Rb1lox/lox mice (Sage et al., 2003), Trp53lox/lox mice (Jonkers et al., 2001),
Skp2+/– mice (Nakayama et al., 2000), and p27–/– mice (Fero et al., 1996)
have been described. POMC-Cre mice (Bradford B. Lowell Laboratory) were
obtained on an FVB background, Rb1lox/lox mice (Tyler Jacks Laboratory) on
a C57BL6J3129Sv background, Trp53lox/lox mice (National Cancer Institute
(NCI) mouse repository) on an FVB3129 background, Skp2–/– mice on
a C57BL6J3129Sv background, p27–/– mice (The Jackson Laboratory) on
a C57BL6J background, and PB-Cre4 mice (NCI mouse repository) on a
C57BL6J3Cg background. Subsequent breeding did not select for or against
any particular strain background. Testing genotypes were studied with control
genotypes from littermates. Genotyping details are provided in the Supple-
mental Information. Animals were housed in the Albert Einstein College of
Medicine animal facility. Mouse procedures were reviewed and approved by
the Albert Einstein College of Medicine Animal Care Committee, conforming
to accepted standards of humane animal care. Mouse pathological studies
were conducted together with the Albert Einstein Cancer Center Mouse
Pathology Core.
Mouse Embryo Fibroblasts, Human Breast Cancer Cell Lines, and
Treatments
MEFs were prepared from embryonic day 13.5 embryos and cultured in Dul-
becco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum
(FBS). Parallel infection with adeno-Cre or adeno-GFP were used to delete orcer Cell 24, 645–659, November 11, 2013 ª2013 Elsevier Inc. 657
Cancer Cell
Blocking pRb/p53 Doubly Deficient Tumorigenesismock-delete Rb1 or/and Trp53 in MEFs containing floxed Rb1 or/and floxed
Trp53. Controls also included infection with adeno-Cre of MEFs without floxed
Rb1 or Trp53. Knockdown or overexpression was carried out by lentiviral
transduction and drug selection with puromycin (catalog no. BP2956-100;
Fisher Scientific) or blasticidin (catalog no. ant-bl-1; InvivoGen). DNA damage
response was generated by treatment with 1 mM DOX (catalog no. BP2516-1;
Fisher Scientific). Human breast cancer cell lines MDA-MB468, BT549,
Hs578T, and HCC1143 (American Type Culture Collection) were cultured in
RPMI 1640 medium containing 10% FBS, 1% penicillin/streptomycin, and
1%glutamine. Knockdown of Skp2 bymiRNAwas achieved by lentiviral trans-
duction at near 100% efficiency. See Supplemental Information for details.
SA-b-gal Staining for Senescence, FACS Analysis for DNA Content
and BrdU Labeling, and Cell Number Counting for Proliferation
Determination
Standard protocols were used; details are in Supplemental Information.
Western Blot Analysis, RT-qPCR, and ChIP
Antibodies used for western blot analysis are Skp2 (H435), cyclin A (C-19), p21
(C-19), Pirh2 (FL261), PCNA (PC10), and Cdk2 (C-19) (all from Santa Cruz
Biotechnology). Mouse anti-p27 antibody was obtained from BD Biosciences
(catalogno.610242),mouseanti-p53antibodywasobtained fromCellSignaling
Technology (catalog no. 1C12) and Santa Cruz Biotechnology (SC-126).
Antibody to a-tubulin was obtained from Sigma-Aldrich (catalog no. T6074).
Antibody to KPC1was described previously (Kamura et al., 2004). See Supple-
mental Information for experimental details and sequences of primers.
Cycloheximide Chase and Serum Starvation Release
For protein stability analysis, MEFs were plated into 60-mm dishes at 70%–
80% confluence. Cycloheximide (CHX, catalog no. 239764; Calbiochem)
was added at 50 mg/ml. At the indicated time points, cell extracts were pre-
pared and western blotted. Quantification of protein levels was performed
using ImageJ software (National Institutes of Health). Serum starvation of
MEFs was carried out in 100-mm dishes at 80%–90% confluence in DMEM
(1% penicillin/streptomycin, 1% glutamine) with 0.2% FBS. After 72 hr, cells
were aliquoted into 60-mm dishes and restimulated with DMEM (1% peni-
cillin/streptomycin, 1% glutamine) containing 10% FBS.
Immunohistochemistry, Immunofluorescence, TUNEL, and
Bromodeoxyuridine Labeling
Antibodies included PCNA (catalog no. PC10; Santa Cruz Biotechnology),
BrdU (catalog no. Ab-2; Calbiochem), pHH3 (Cell Signaling Technology),
Ki67 (catalog no. SP6; Vector Laboratories), activated caspase 3 (catalog
no. 9664S; Cell Signaling Technology), mouse anti-p27 antibody (catalog
no. 610242; BD Biosciences), and rabbit anti-p27 antibody (catalog no.
ab92741; Abcam). TUNEL staining was performedwith an apoptosis detection
kit (catalog no. S7100; EMD Millipore). For BrdU labeling, mice were injected
with 0.4% BrdU (B5002; Sigma-Aldrich) at 25 ml/g body weight 2 hr before
they were killed. See Supplemental Information for experiment details.
Statistical Analysis
In the survival analysis, differences in Kaplan-Meier survival curves were
analyzed using a logrank test with GraphPad Prism 6 software (GraphPad
Software). Differences in Ki67-, pHH3-, BrdU-, and TUNEL-positive cells be-
tween indicated samples were analyzed by Student’s t test. P values < 0.05
were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.09.021.
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